Key facts
- It has raised $2.0M; the latest was Early Stage VC in Sep 2025.
- Notable investors include 3E Bioventures Capital, Liquidmetal Ventures, LongRiver Investments.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Retex Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Retex Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Retex Pharmaceuticals
Developer of therapeutic medicines intended to cure disease. The company engages in developing novel medicines for chronic diseases by targeting ion channels and GPCRs, enabling doctors to cure patients.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2022
- Employees
- 3
- Website
- retexpharma.com/
- Ownership
- Privately Held (backing)
Retex Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Retex Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Retex Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.